吡嗪-2-硼酸频哪醇酯 | 1083179-99-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 吡嗪-2-硼酸频哪醇酯
• 中文别名: 吡嗪-2-硼酸频那醇酯
• 英文名称: 2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazine
• CAS: 1083179-99-0
• 化学式: C₁₀H₁₅BN₂O₂
• 分子量: 206.052
• InChiKey: OERCBFJFHINDNO-UHFFFAOYSA-N

物化性质

• 沸点：
  306.3±22.0 °C(Predicted)
• 密度：
  1.07

计算性质

• 辛醇/水分配系数(LogP)：
  0.78
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  44.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  吡嗪-2-硼酸频哪醇酯 、 5-bromo-3-phenyl-1-(tetrahydro-pyran-2-yl)-1H-pyrazolo[3,4-c]pyridine 以to give 214 as a yellow solid (22 mg, 28%) over two steps的产率得到3-phenyl-5-(pyrazin-2-yl)-1H-pyrazolo[3,4-c]pyridine
  参考文献：
  名称：

  PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE

  摘要：

  公式I中的Pyrazolo [3,4-c] pyridine化合物，包括立体异构体，几何异构体，互变异构体和其药学上可接受的盐，其中R1和R2如本文所定义，可用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式I中化合物进行哺乳动物细胞中的体外，原位和体内诊断，预防或治疗此类疾病或相关病理条件的方法。

  公开号：

  US20130039906A1

文献信息

• [EN] PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT<br/>[FR] DÉRIVÉS DE PIPÉRAZINE ET LEUR UTILISATION EN TANT QUE MÉDICAMENT
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2015055698A1

  公开（公告）日：2015-04-23

  The present inventions relate to substituted piperazine derivatives of general formula (I) and to the manufacture of said compounds, pharmaceutical compositions comprising a compound according to general formula (I), and the use of said compounds for the treatment of various medical conditions related to glycine transporter-1 (GlyT1).

  这些发明涉及一般式(I)的取代哌嗪衍生物，以及制备该化合物、包含符合一般式(I)的化合物的药物组合物，以及利用该化合物治疗与甘氨酸转运蛋白-1（GlyT1）相关的各种医疗状况。
• Pyrazolo[3,4-c]pyridine compounds and methods of use
  申请人：Do Steven

  公开号：US09260425B2

  公开（公告）日：2016-02-16

  Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  本发明提供了式I的吡唑并[3,4-c]吡啶化合物，包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐。其中，R1和R2如本文所定义，可用于抑制Pim激酶并治疗由Pim激酶介导的癌症等疾病。本发明还公开了使用式I的化合物在哺乳动物细胞中进行体外、体内和原位诊断、预防或治疗此类疾病或相关病理状态的方法。
• Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors
  作者：Matthew T. Burger、Mark Knapp、Allan Wagman、Zhi-Jie Ni、Thomas Hendrickson、Gordana Atallah、Yanchen Zhang、Kelly Frazier、Joelle Verhagen、Keith Pfister、Simon Ng、Aaron Smith、Sarah Bartulis、Hanne Merrit、Marion Weismann、Xiaohua Xin、Joshua Haznedar、Charles F. Voliva、Ed Iwanowicz、Sabina Pecchi

  DOI：10.1021/ml1001932

  日期：2011.1.13

  Phospoinositide-3-kinases (PI3K) are important oncology targets due to the deregulation of this signaling pathway in a wide variety of human cancers. series of 2 morpholino, 4-substituted, 6-(3-hydroxyphenyl) pyrimidines have been reported as potent inhibitors of PI3Ks. Herein, we describe the structure guided optimization of these,pyrimidines with a focus on replacing the phenol moiety, while maintaining potent target inhibition and improving in vivo properties A series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines, which potently inhibit PI3K, were discovered,Within-this series a compound, 17, Was identified with suitable pharmacokinetic (PK) properties, which allowed for the establishment of a PI3K PK/pharmacodynamic-efficacy relationship as determined by in vivo inhibition of AKT(Ser473) phosphorylation and tumor growth inhibition in a mouse A2780 tumor xenograft model.
• WO2020150474A5
  申请人：——

  公开号：WO2020150474A5

  公开（公告）日：2022-07-28
• Discovery of potent, selective small molecule inhibitors of α-subtype of type III phosphatidylinositol-4-kinase (PI4KIIIα)
  作者：Piotr Raubo、David M. Andrews、Jennifer C. McKelvie、Graeme R. Robb、James M. Smith、Martin E. Swarbrick、Michael J. Waring

  DOI：10.1016/j.bmcl.2015.05.093

  日期：2015.8

  The discovery and optimisation of novel, potent and selective small molecule inhibitors of the alpha-isoform of type III phosphatidylinositol-4-kinase (PI4K alpha) are described. Lead compounds show cellular activity consistent with their PI4K alpha potency inhibiting the accumulation of IP1 after PDGF stimulation and reducing cellular PIP, PIP2 and PIP3 levels. Hence, these compounds are useful in vitro tools to delineate the complex biological pathways involved in signalling through PI4Ka. (C) 2015 Elsevier Ltd. All rights reserved.